
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc is positioned favorably in the biotechnology sector due to its innovative approach to developing allogeneic gamma delta T cell therapies, particularly with its product candidate ADI-001, which demonstrates promising efficacy and a favorable safety profile compared to traditional autologous CAR-T therapies. The anticipated upcoming clinical readout and initiation of further studies in 2026 are expected to provide significant catalysts for the company's growth. Furthermore, the strategy of utilizing third-party manufacturers for large-scale production helps mitigate manufacturing risks, enhancing the overall viability of Adicet's offerings and bolstering its competitiveness in the marketplace.
Bears say
Adicet Bio Inc faces a negative financial outlook primarily due to projected net losses, with expectations of a $1.13 per share loss for 2025, signaling ongoing financial strain. The company grapples with significant risks, including the potential for lower efficacy of its lead candidate, ADI-001, in patients previously treated with anti-CD20 therapies, and heightened competition could further erode projected market share and revenue generation. Compounding these concerns, the lowered probability of success for ADI-001 in critical indications and increased regulatory risks from unapproved gamma-delta T-cell therapies contribute to skepticism regarding the company's growth prospects and overall financial stability.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares